Evidence map›Paper›PMID 40570551›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Subjective drug-effect ratings predict cannabis self-administration in people who use cannabis daily.

Thomas P Shellenberg, Justin C Strickland, Sean D Regnier, Preston T Tolbert, Stephanie Lake, Michael J Wesley, William W Stoops, Ziva D Cooper, Margaret Haney, Joshua A Lile

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Thomas P ShellenbergDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, Kentucky.
Justin C StricklandDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Sean D RegnierDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky.
Preston T TolbertDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Biostatistics, University of Kentucky College of Public Health, Lexington, Kentucky.
Stephanie LakeJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences and Department of Anesthesiology and Perioperative Medicine, UCLA, Los Angeles, California.
Michael J WesleyDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, Kentucky.
William W StoopsDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, Kentucky; Department of Psychiatry, University of Kentucky College of Medicine, Lexington, Kentucky.
Ziva D CooperJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences and Department of Anesthesiology and Perioperative Medicine, UCLA, Los Angeles, California.
Margaret HaneyDepartment of Psychiatry, Division on Substance Use Disorders, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, New York.
Joshua A LileDepartment of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky; Department of Psychology, University of Kentucky College of Arts and Sciences, Lexington, Kentucky; Department of Psychiatry, University of Kentucky College of Medicine, Lexington, Kentucky. Electronic address: jalile2@uky.edu.

Funding

PHARMACOLOGICAL TREATMENT OF MARIJUANA DEPENDENCEP50DA009236 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI KLEBER, HERBERT DAVID · 1994 to 2013
$39.4M
Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
Sex-dependent effects of cannabis: Assessing abuse-related and pharmacokinetic differences between men and womenR01DA047296 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COOPER, ZIVA D · 2019 to 2024
$3.5M
Age-and sex-dependent pharmacodynamics and pharmacokinetics of oral and smoked delta-9-THCR01DA057252 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZIVA D COOPER · 2022 to 2026
$2.6M
Medication Development for Marijuana RelapseR01DA019239 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI HANEY, MARGARET · 2004 to 2008
$2.5M
Human Laboratory Screening of Pregabalin and Tiagabine for Cannabis DependenceR01DA036550 · NIDA · UNIVERSITY OF KENTUCKY · PI LILE, JOSHUA ANTHONY · 2014 to 2019
$2.1M
GABA Drugs for Cannabis-Use Disorders: Initial Mechanistic Studies in HumansR01DA025605 · NIDA · UNIVERSITY OF KENTUCKY · PI LILE, JOSHUA ANTHONY · 2008 to 2011
$1.4M
NIDA NIH HHS P50 DA009236NIDA NIH HHS R01 DA019239NIDA NIH HHS R01 DA025605NIDA NIH HHS R01 DA036550NIDA NIH HHS R01 DA047296NIDA NIH HHS R01 DA057252NIDA NIH HHS T32 DA035200
6 · The paper itself

Abstract

As interest in the potential therapeutic benefits of cannabis-derived products grows, accurate predictors of abuse potential will be vital for informing regulatory decisions. Currently, the Food and Drug Administration recommends using subjective effect ratings of Drug Liking as the primary measure in human abuse potential studies. However, dissociations between subjective ratings and drug-taking behavior have been previously reported. This retrospective analysis determined if any subjective effects questionnaire items uniquely predicted cannabis self-administration in people who use cannabis daily (N = 89; 71 male and 18 female). Data from 4 previous studies across 2 research sites that included cannabis self-administration and subjective effects assessments were combined. Concentrations of Δ

Indexed as

CannabisAdolescentAdultDronabinolFemaleHumansMaleMiddle AgedRetrospective StudiesSelf AdministrationSurveys and QuestionnairesYoung AdultDronabinolCannabis self-administrationHuman abuse potential studiesSubjective drug-effect ratings

Identifiers

PMID40570551
PMCPMC12556786

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.